Stockreport

Lexeo Therapeutics GAAP EPS of -$0.89 misses by $0.24 [Seeking Alpha]

Lexeo Therapeutics, Inc.  (LXEO) 
PDF As of September 30, 2024, cash and cash equivalents were $157.0 million, which Lexeo believes will be sufficient to fund operations into 2027. More on Lexeo Therapeut [Read more]